Article
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
The lancet. Diabetes & endocrinology - 1 Aug 2018
Bowman Pamela, Sulen Åsta, Barbetti Fabrizio, Beltrand Jacques, Svalastoga Pernille, Codner Ethel, Tessmann Ellen H, Juliusson Petur B, Skrivarhaug Torild, Pearson Ewan R, Flanagan Sarah E, Babiker Tarig, Thomas Nicholas J, Shepherd Maggie H, Ellard Sian, Klimes Iwar, Szopa Magdalena, Polak Michel, Iafusco Dario, Hattersley Andrew T, Njølstad Pål R
Abstract excerpt
BACKGROUND: KCNJ11 mutations cause permanent neonatal diabetes through pancreatic ATP-sensitive potassium channel activation. 90% of patients successfully transfer from insulin to oral sulfonylureas with excellent initial glycaemic control; however, whether this control is maintained in the long term is unclear. Sulfonylurea failure is seen in about 44% of people with type 2 diabetes after 5 years of treatment....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.